Benitec Biopharma Inc's Comment on Sales, Marketing and Customers
The company is a clinical-stage biotechnology firm developing therapeutic biological products regulated by the U.S. Food and Drug Administration (FDA) and other regulatory agencies. It plans to seek approval for testing and marketing its products in multiple regions, including the European Union, where gene therapy products are classified as advanced therapy medicinal products (ATMPs) and require authorization from the European Medicines Agency (EMA). The company’s products, if approved, are expected to be priced at a premium compared to competitive therapies. Insurers and third-party payers may promote the use of alternative products, such as biosimilars or generics, which could impact the company’s competitive position. Regulatory requirements may delay or prevent product testing or marketing and impose significant costs.
Positive Clinical Outcomes for Benitec Biopharma’s BB-301 in Phase 1b/2a Study Amidst Market Performance Struggles Benitec Biopharma Inc. has recently reported promising results from its Phase 1b/2a clinical study of BB-301, a gene therapy aimed at treating patients with swallowing disorders. The data was presented at the 29th Annual Congress of the World Muscle Society and highlighted significant improvements in swallowing function in two treated subjects.Key findings from the study indicate that both Subject 1 and Subject 2 exhibited durable, clinically meaningful improvements in their ability to swallow. Remarkably, Subject 2 achieved a score on the Sydney Swallow Questionnaire that was representative o...
: Oculopharyngeal Muscular Dystrophy (OPMD) is a rare, inherited disorder that predominantly affects the muscles involved in swallowing. Benitec Biopharma, a renowned biotechnology company, has reported promising results from their Phase 1b/2a clinical trial assessing the safety and efficacy of gene therapy candidate BB-301 as a potential treatment for OPMD. This article aims to summarize the key findings, demonstrating continued durable improvements in swallowing efficiency and patient-reported outcomes for the first OPMD subject treated with low-dose BB-301 at the 180-day post-dose assessment. The study utilized Benitec s innovative Silence and Replace DNA-directed RNA interference gene therapy platform, m...
Benitec Biopharma Inc’s Comment on Sales, Marketing and Customers
The company is a clinical-stage biotechnology firm developing therapeutic biological products regulated by the U.S. Food and Drug Administration (FDA) and other regulatory agencies. It plans to seek approval for testing and marketing its products in multiple regions, including the European Union, where gene therapy products are classified as advanced therapy medicinal products (ATMPs) and require authorization from the European Medicines Agency (EMA). The company’s products, if approved, are expected to be priced at a premium compared to competitive therapies. Insurers and third-party payers may promote the use of alternative products, such as biosimilars or generics, which could impact the company’s competitive position. Regulatory requirements may delay or prevent product testing or marketing and impose significant costs.
Sources:
Benitec Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Benitec Biopharma Inc’s corporate clients.
For your research, we’ve provided 9 tables on Benitec Biopharma Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
